Compare Novo Nordisk A/S (NVO) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ThredUp Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while ThredUp Inc trades at $2.48 (market cap $308.63M). The key difference: Novo Nordisk A/S is far larger — about 535.6× ThredUp Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and ThredUp Inc for 29 Days on average.
| NVO | TDUP | |
|---|---|---|
Market Cap | $165.31B | $308.63M |
Volume | 11,432,838 | 3,024,364 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $9.41 |
52-Week Low | $35.29 | $2.12 |
Typical Hold Time | 116 Days | 29 Days |
Enterprise Value | $179.56B | $306.81M |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
ThredUp (TDUP) trades at $2.48, up 11.71% in the last session, yet remains in a bearish technical trend. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed EPS estimates and cut full-year revenue guidance. Despite a high gross margin of 79.52%, it posted a net loss margin of -6.65% and negative ROE. Analyst consensus is 57% buy, but recent news highlights a fraud investigation and promotional headwinds.
The outlook is mixed: strong revenue growth and a dominant position in online resale offer upside, but persistent losses, weak guidance, and legal risks pose significant challenges. Investors should weigh the bullish analyst ratings against fundamental weaknesses and recent stock volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
